A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies

Trial Profile

A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Adegramotide/nelatimotide (Primary) ; Adegramotide/nelatimotide (Primary)
  • Indications Acute myeloid leukaemia; Glioblastoma; Malignant melanoma; Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Sarcoma
  • Focus Adverse reactions
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 20 Oct 2017 Treatment arms has been increased from 1 to 3 and patients number also increases.
    • 20 Oct 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Aug 2018.
    • 20 Oct 2017 Planned number of patients changed from 76 to 96.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top